In a groundbreaking medical achievement, STENTiT, a Dutch medical device company, has successfully implanted its Resorbable Fibrillated Scaffold (RFS) in a patient suffering from chronic limb-threatening ischemia (CLTI). This innovative stent, implanted in Austria in July 2025, marks a significant step forward in regenerative vascular treatments.
The RFS is a fully bioresorbable stent made from microfibers, designed to support the artery while promoting natural tissue regeneration. Its porous structure allows the patient's own cells to infiltrate the mesh, fostering new vascular tissue growth from within. Over time, the implant dissolves, leaving no permanent material behind.
This initial implantation is part of the VITAL-IT 1 study, which aims to evaluate the safety and performance of the RFS device in patients with below-the-knee CLTI. The study's results could revolutionize the treatment of severe vascular conditions and reduce the need for amputations, which affect hundreds of thousands of people annually.